drug_type
RELEVANT_DRUG
intervention_type
antibody-drug conjugate
drug_description
HER2-directed antibody-drug conjugate linking trastuzumab to the maytansinoid microtubule inhibitor DM1, delivering the cytotoxic payload to HER2-expressing cancer cells to disrupt microtubules and inhibit proliferation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ado-Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-directed antibody-drug conjugate linking trastuzumab to the maytansinoid DM1. Binds HER2 on tumor cells, is internalized, and releases DM1 intracellularly to inhibit microtubule function, causing mitotic arrest and apoptosis; also retains trastuzumab-mediated HER2 signaling blockade and ADCC.
drug_name
Trastuzumab emtansine (T-DM1)
nct_id_drug_ref
NCT06968585